Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Sarcomas of Extra-Mesenchymal Sites
share announcement

Sarcomas of Extra-Mesenchymal Sites

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".

Deadline for manuscript submissions: closed (31 August 2023) | Viewed by 2681

Special Issue Editor

Dr. Thérèse Bocklage

E-Mail Website
Guest Editor
Department of Pathology, University of Kentucky College of Medicine and Markey Cancer Center, Lexington, KY 40536, USA
Interests: head and neck cancer; bone and soft tissue tumors; pathology

Special Issue Information

Dear Colleagues,

In this Special Issue, we provide an essential update on sarcomas arising in extra-mesenchymal sites of viscera as well as head and neck. Sarcomas are both rare and highly diverse, with more than 75 sarcoma types described in the W.H.O. Soft Tissue and Bone Tumours 5th edition fascicle. Accurate diagnosis can be challenging, as tumors may overlap in clinical presentation, imaging appearance and histologic features, and molecular genetic evaluation may be required to determine the specific diagnosis. While most sarcomas arise in mesenchymal tissue such as dermis, fat, muscle and bone, a subset originate in viscera and head and neck, and a few occur exclusively in extra-mesenchymal sites. In the setting of ongoing refinements in sarcoma diagnosis, prognostication and treatment, this review summarizes key features of extra-mesenchymal sarcomas: the epidemiology of these tumors, the diagnostic pathology and molecular genetics of specific entities, clinical presentation range, imaging characteristics and current and upcoming treatment approaches.

Dr. Thérèse Bocklage 
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • extra-mesenchymal sarcomas
  • epidemiology
  • pathology
  • molecular genetics
  • treatment

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

16 pages, 715 KiB  
Review
Pediatric Rhabdomyosarcomas of the Genitourinary Tract
by Jennifer T. Castle, Brittany E. Levy, Derek B. Allison, David A. Rodeberg and Eric J. Rellinger
Cancers 2023, 15(10), 2864; https://doi.org/10.3390/cancers15102864 - 22 May 2023
Cited by 1 | Viewed by 2346
Abstract
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in the pediatric and adolescent population, with 350 new cases diagnosed each year. While they can develop anywhere in the body, the genitourinary tract is the second most common primary location for an RMS [...] Read more.
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in the pediatric and adolescent population, with 350 new cases diagnosed each year. While they can develop anywhere in the body, the genitourinary tract is the second most common primary location for an RMS to develop. Overall survival has improved through the increased use of protocols and multidisciplinary approaches. However, the guidelines for management continue to change as systemic and radiation therapeutics advance. Given the relative rarity of this disease compared to other non-solid childhood malignancies, healthcare providers not directly managing RMS may not be familiar with their presentation and updated management. This review aims to provide foundational knowledge of the management of RMSs with an emphasis on specific management paradigms for those arising from the genitourinary tract. The genitourinary tract is the second most common location for an RMS to develop but varies greatly in symptomology and survival depending on the organ of origin. As the clinical understanding of these tumors advances, treatment paradigms have evolved. Herein, we describe the breadth of presentations for genitourinary RMSs with diagnostic and treatment management considerations, incorporating the most recently available guidelines and societal consensus recommendations. Full article
(This article belongs to the Special Issue Sarcomas of Extra-Mesenchymal Sites)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop